Key facts
- Australis Scientific’s last known valuation is $26.5M (Nov 2023).
- It has raised $12.8M; the latest was Early Stage VC ($6.1M) in Nov 2025.
- Notable investors include MedTech Innovator, Harvard Innovation Launch Lab, 10XBeta, Butterworth Investments, NSW Medical Devices Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Australis Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for Australis Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Australis Scientific
Developer of a neural modulation technology intended to revolutionize the treatment of LUTS (lower urinary tract symptoms). The company's smart patch technology treats patients' lower urinary tract symptoms, including frequency, urgency, and nocturia, enabling individuals to get treated with neuromodulation device therapy based on their symptoms.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2021
- Employees
- 7
- Website
- australisscientific.com/
- Ownership
- Privately Held (backing)
Australis Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Australis Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Australis Scientific in its N-PORT filings yet. We sweep new filings monthly.